UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR) had its price target cut by UBS Group from $80.00 to $74.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms also recently weighed in on KYMR. Leerink Partners reiterated an “outperform” rating and set a $60.00 price target on shares of Kymera Therapeutics in a research note on Monday, September 9th. Wells Fargo & Company boosted their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an “equal weight” rating in a research report on Monday, August 12th. Morgan Stanley raised their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 14th. Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Oppenheimer increased their target price on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Four investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $51.21.

Kymera Therapeutics Stock Performance

Shares of KYMR stock opened at $49.86 on Monday. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -21.73 and a beta of 2.21. Kymera Therapeutics has a 52 week low of $13.85 and a 52 week high of $53.27. The firm’s 50-day simple moving average is $46.98 and its two-hundred day simple moving average is $40.99.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. During the same quarter in the previous year, the firm posted ($0.90) EPS. Kymera Therapeutics’s revenue was down 20.9% on a year-over-year basis. Analysts forecast that Kymera Therapeutics will post -2.83 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 6.7% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,471 shares of the company’s stock valued at $984,000 after purchasing an additional 1,531 shares during the last quarter. FORA Capital LLC bought a new position in shares of Kymera Therapeutics during the first quarter valued at about $818,000. Jennison Associates LLC bought a new position in shares of Kymera Therapeutics during the first quarter valued at about $17,122,000. Nvwm LLC purchased a new position in shares of Kymera Therapeutics in the first quarter worth about $294,000. Finally, Swiss National Bank lifted its stake in shares of Kymera Therapeutics by 12.3% in the 1st quarter. Swiss National Bank now owns 79,700 shares of the company’s stock valued at $3,204,000 after acquiring an additional 8,700 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.